Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937627 | 0.81 | FAAH (0.38) | MEN1KMT2AMGLLCTSGCMA1 | |
| SCHEMBL22728437 | 0.81 | KMT2A (0.43) | KMT2AMGLLPOLBNPC1RAB9A | |
| SCHEMBL29420242 | 0.73 | BCAT2 (0.65) | HSD11B1MEN1KMT2ADRD2DRD3 | |
| SCHEMBL29163639 | 0.73 | BCAT2 (0.65) | HSD11B1MEN1KMT2ADRD2DRD3 | |
| SCHEMBL22330263 | 0.71 | ALDH1A1 (0.47) | DRD3L3MBTL1HPGD | |
| SCHEMBL31318721 | 0.70 | ALOX5 (0.43) | ALOX5MEN1KMT2ACTSGCMA1 | |
| SCHEMBL9819245 | 0.70 | CRBN (0.71) | ALOX5HSD11B1MEN1KMT2ANPC1 | |
| SCHEMBL1703944 | 0.69 | ALDH1A1 (0.62) | ALOX5NPC1HPGDRAB9A | |
| SCHEMBL29930316 | 0.69 | ALDH1A1 (0.62) | ALOX5NPC1HPGDRAB9A | |
| SCHEMBL17699653 | 0.69 | ALDH1A1 (0.49) | ALOX5HSD11B1MEN1KMT2AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171578-A1 | Pyrrolidinone derivative compound | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-11 | — | — | US | disclosed |
| EP-0916656-B1 | A method for production of pyrrolidinone derivatives | SCHERING AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-6555694-B1 | Reacting an aniline and cyclopropane-1,1-dicarboxylic acid; free of hydrogen-generating substance and moisture sensitive reagent; corrosion resistance; simplification; for piperazine derivatives used as central nervous system disorders | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| US-6207825-B1 | REACTING THE CORRESPONDING 3-CARBOXYPYRROLIDINONE COMPOUND IN THE PRESENCE OF FORMALDEHYDE | MITSUI CHEMICALS, INC. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0916656-A2 | A method for production of pyrrolidinone derivatives | Mitsui Chemicals, Inc. (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171578-A1 | Pyrrolidinone derivative compound | PFAS, CBR1, PYCR1 | ALOX5 548/4885HSD11B1 20/4885MEN1 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.